Publications




Melanoma brain metastases harboring BRAFor NRAS mutations are associated with an increased local failure rate following conventional therapy.
J Neurooncol 2017 Dec 2. Epub 2017 Dec 2.
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 97, Houston, TX, 77030, USA.

MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma.
Cancer Cell 2017 Dec;32(6):840-855.e8
Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. Electronic address:

GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma.
Cell Rep 2017 Nov;21(8):2183-2197
Glioma and Neural Stem Cell Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors Team, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Electronic address:

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
Neuro Oncol 2017 Oct;19(11):1469-1480
Pathobiology and Translational Science Graduate Program, Departments of Pathology and Laboratory Medicine, Biology, Pharmacology, Genetics, Medicine, and Neurology, Divisions of Neuropathology and Hematology/Oncology, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, Proteomics Core Facility, Neurosciences Center, Carolina Institute for Developmental Disabilities, and Biological and Biomedical Sciences Program, University of North Carolina (UNC) School of Medicine, Chapel Hill, North Carolina; Cancer & Cell Biology Division, TGen, Phoenix, Arizona; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota; Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.





Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Neuro Oncol 2017 Jul;19(7):965-975
Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; Neuro-Oncology Unit, Erasmus MC Cancer Center, Rotterdam, the Netherlands; Department of Neurology, Northwestern University, Chicago, Illinois; Department of Neurology, NorthShore University HealthSystem, Evanston, Illinois; Department of Medical Oncology, Austin Health and Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia; School of Cancer Medicine, La Trobe University School of Cancer Medicine, Melbourne, Victoria, Australia; South Texas Accelerated Research Therapeutics (START), San Antonio, Texas; Department of Radiation Oncology, The University of Texas M.D.Anderson Cancer Center, Houston, Texas; AbbVie Inc., North Chicago, Illinois; Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.
Cancer Cell 2017 Jul;32(1):42-56.e6
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA. Electronic address:

mA Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program.
Cancer Cell 2017 Apr 23;31(4):591-606.e6. Epub 2017 Mar 23.
Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Program in Cancer Biology, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA. Electronic address:


A Dexamethasone-regulated Gene Signature Is Prognostic for Poor Survival in Glioblastoma Patients.
J Neurosurg Anesthesiol 2017 Jan;29(1):46-58
*Department of Anesthesiology, Bern University Hospital Inselspital, Bern, Switzerland Departments of †Cancer Systems Imaging ‡Diagnostic Imaging §Neurosurgery and Brain Tumor Center ∥Radiation Oncology, Division of Radiation Oncology #Neurosurgery, Cancer Systems Imaging, and Cancer Biology **Cancer Systems Imaging, and Diagnostic Imaging, The University of Texas MD Anderson Cancer Center ¶Department of Neurosurgery, Baylor College of Medicine, Houston, TX.

Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline.
J Clin Oncol 2017 Jan 28;35(3):361-369. Epub 2016 Nov 28.
Erik P. Sulman and Terri S. Armstrong, MD Anderson Cancer Center; Terri S. Armstrong, University of Texas Health Science Center, Houston, TX; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Christina Tsien, Washington University Physicians, St Louis, MO; Tracy T. Batchelor, Massachusetts General Hospital, Boston, MA; Tim Cloughesy, University of California, Los Angeles, Los Angeles; Mary Lovely and Susan M. Chang, University of California, San Francisco, San Francisco, CA; Evanthia Galanis, Mayo Clinic, Rochester, MN; Mark Gilbert, National Cancer Institute, Bethesda; Minesh Mehta, University of Maryland School of Medicine, Baltimore, MD; Vinai Gondi, Northwestern Medicine Cancer Center, Warrenville, IL; Matthew P. Mumber, Harbin Clinic Radiation Oncology, Rome, GA; and Andrew Sloan, University Hospitals Cleveland Medical Center, Cleveland, OH.


Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
J Natl Cancer Inst 2016 May 27;108(5). Epub 2015 Nov 27.
Department of Radiation Oncology (SKG, BLC, ACM, KKB, JLP, MAS, LC, GJK, JNS), Division of Medical Oncology (SHK), Molecular Pharmacology and Experimental Therapeutics (FBA, JMR), Division of Biomedical Statistics and Informatics (PAD, JEEP, KVB), and Laboratory Medicine and Pathology (GS, RBJ), Mayo Clinic, Rochester MN; The University of Texas, MD Anderson Cancer Center, Houston, TX (RGV, EPS).

TERT Promoter Mutations and Risk of Recurrence in Meningioma.
J Natl Cancer Inst 2016 May 13;108(5). Epub 2015 Dec 13.
Affiliations of authors:Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg , Heidelberg , Germany (FS, DS, CK, DR, JB, AK, DC, SS, AvD); Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg , Germany (FS, DS, CK, DR, AK, DC, AvD); Department of Pathology (AO), Department of Genomic Medicine (QW), Department of Radiation Oncology (QW, EPS), and Department of Bioinformatics and Computational Biology (QW), The University of Texas MD Anderson Cancer Center , Houston, TX ; Department of Radiation Oncology (SA, JD) and Department of Neurosurgery (MSc, TU, CHM), University Hospital Heidelberg , Heidelberg , Germany ; Department of Neuropathology, Charité Medical University , Berlin , Germany (AK); Department of Pathology, University Hospital Nürnberg , Nürnberg , Germany (AFO): Department of Neurosurgery, Medical Faculty of the Ruprecht-Karls-University of Heidelberg , Mannheim , Germany (SB); Department of Neuropathology, Institute of Pathology and Neuropathology, University Tübingen , Tübingen , Germany (JS); Department of Neuropathology, University of Bonn , Bonn , Germany (AB); Department of Neurosurgery (BB) and Institute of Neuropathology (WP), University Hospital Münster , Münster , Germany (BB); Department of Neurosurgery, University Hospital Bonn , Bonn , Germany (KG, MSi); Department of Neurosurgery, University Hospital Würzburg , Würzburg , Germany (AFK); Department of Neurosurgery, University Hospital Hamburg , Hamburg , Germany (KL); Department of Neuropathology, Otto von Guericke University Magdeburg , Magdeburg , Germany (CM); Institute of Pathology, Saarland University , Homburg, Saarland , Germany (YJK); Department of Neurosurgery, Saarland University , Homburg , Germany (RK); MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Center , Toronto, Ontario , Canada (KDA); Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg , Germany (TH).



Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy.
Radiother Oncol 2015 Nov 16;117(2):308-14. Epub 2015 Oct 16.
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States. Electronic address:

Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.
J Neurosci 2015 Nov;35(45):15097-112
Departments of Genetics, Neuro-Oncology, The Brain Tumor Center, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, The University of Texas Graduate School of Biomedical Sciences, Houston, Texas 77030

Genetic Modulation of Neurocognitive Function in Glioma Patients.
Clin Cancer Res 2015 Jul 22;21(14):3340-6. Epub 2015 Apr 22.
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.


Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
N Engl J Med 2015 Jun 10;372(26):2481-98. Epub 2015 Jun 10.



Systematic identification of single amino acid variants in glioma stem-cell-derived chromosome 19 proteins.
J Proteome Res 2015 Feb 25;14(2):778-86. Epub 2014 Nov 25.
Department of Pharmacology and Toxicology and ‡Biochemistry and Molecular Biology, UTMB Cancer Center, University of Texas Medical Branch , Galveston, Texas 77555, United States.

EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner.
Stem Cell Reports 2015 Feb 15;4(2):226-38. Epub 2015 Jan 15.
Department of Neurological Surgery, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. Electronic address:

A randomized trial of bevacizumab for newly diagnosed glioblastoma.
N Engl J Med 2014 Feb;370(8):699-708
From the University of Texas M.D. Anderson Cancer Center (M.R.G., T.S.A., J.S.W., P.D.B., I.W.T.-L., E.P.S., K.D.A.) and the University of Texas Health Science Center School of Nursing (T.S.A.), Houston; American College of Radiology (J.J.D., S.P., M.W.) and Thomas Jefferson University (M.W.-W.) - both in Philadelphia; the University of Chicago, Chicago (J.J.D.); Tel-Aviv Medical Center, Tel Aviv, Israel (D.T.B.); Cleveland Clinic, Cleveland (M.A.V.); the University of Utah, Salt Lake City (H.C.); Ohio State University, Columbus (A.C.); University of Wisconsin, Madison (R.J.); Mayo Clinic, Jacksonville, FL (K.A.J.); University of Virginia, Charlottesville (D.S.); Southeast Cancer Control Consortium, Winston-Salem, NC (V.W.S.); Barrow Neurologic Institute, Phoenix, AZ (D.G.B.); Emory University, Atlanta (W.J.C.); and the University of Maryland, Baltimore (M.P.M.).



IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.
Neuro Oncol 2014 Jan 4;16(1):81-91. Epub 2013 Dec 4.
Corresponding author: Daniel P. Cahill, MD, PhD, Department of Neurosurgery, 32 Fruit Street - Yawkey 9E, Massachusetts General Hospital, Brain Tumor Center/Neuro-Oncology, Boston, MA 02114.



Predictors of survival in contemporary practice after initial radiosurgery for brain metastases.
Int J Radiat Oncol Biol Phys 2013 Mar 14;85(3):656-61. Epub 2012 Aug 14.
Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.






MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.
Neuro Oncol 2010 Feb 14;12(2):116-21. Epub 2009 Dec 14.
Departments of Pathology and Radiation-Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit-0097, Houston, TX 77030, USA.


Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation.
Int J Radiat Oncol Biol Phys 2007 Dec 27;69(5):1409-16. Epub 2007 Sep 27.
Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.


A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways.
Nat Commun 2016 10 4;7:12885. Epub 2016 Oct 4.
Department of Neurology, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA.

TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1.
Sci Adv 2016 04 1;2(4):e1501290. Epub 2016 Apr 1.
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.



OF